Comparative Pharmacology
Head-to-head clinical analysis: E MYCIN E versus PEDIAMYCIN 400.
Peer-Reviewed Evidence
Head-to-head clinical analysis: E MYCIN E versus PEDIAMYCIN 400.
E-MYCIN E vs PEDIAMYCIN 400
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Erythromycin binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis by blocking the translocation of peptide chains.
Erythromycin binds to the 50S subunit of the bacterial ribosome and inhibits protein synthesis by blocking the translocation step.
250-500 mg orally every 6 hours or 333-500 mg every 8 hours; maximum 4 g/day.
400 mg orally every 6 hours for 10 days.
None Documented
None Documented
Terminal elimination half-life is 1.5-3 hours in adults; prolonged to 4-6 hours in neonates and patients with hepatic impairment.
1.5-2 hours; prolonged in renal impairment (up to 6 hours)
Primarily excreted unchanged in urine (70-80%) via glomerular filtration and tubular secretion; 15-20% excreted in feces via biliary elimination.
Renal (80-90% unchanged); biliary/fecal (minor, <5%)
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic